Veterinary medicine and animal agriculture had our chance to deal with paratuberculosis before it became an epidemic. Today, 121 years since Heinrich Albert Johne described paratuberculosis in a Guernsey cow in Germany, well over half of all dairy herds in virtually all major dairy-producing countries are infected with M. paratuberculosis. It is almost certain that humans are becoming infected and that the most probable means of infection is via the food supply.
Read more about the facts, predictions and what can be done to control M. paratuberculosis in Dr. Michael T. Collins’ 2016 World Buiatrics Congress Keynote Address.
The MAP Gap Newsletter | July 2016
The Crohns Infection is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together.
Here are some of the most recent developments in the area of MAP related Crohn’s Research. Enjoy!
The Dietzia Foundation
The Crohn’s Infection is pleased to announce the newly created Dietzia Foundation! From their website, “Dietzia Foundation is a publicly supported nonprofit organization dedicated to supporting scientific medical research in the field of gastroenterology. Specifically, we support those trying to develop preventative or therapeutic treatments for gastrointestinal dysbiosis associated diseases like Crohn’s disease, ulcerative colitis and others.”
The Crohn’s Infection Turns One!
It doesn’t seem possible, but on June 21, 2016, The Crohn’s Infection site will officially be one year old. Join us as we highlight some of the key site features and enter our first site contest. Thanks for coming to the party!
AMAT: Together We Are Stronger
On June 14, 2016, the journal Gut Pathogens released a new study entitled “RHB-104 Triple Antibiotics Combination in Culture is Bactericidal and Should be Effective for Treatment of Crohn’s Disease Associated with Mycobacterium paratuberculosis.” The researchers from the University of Central Florida (including Dr. Saleh Naser) found that the raw active ingredients used in RHB-104 worked together in combination to inhibit the growth of 16 Mycobacterium avium paratuberculosis (MAP) strains and 19 other mycobacterial species.